famotidine has been researched along with Cancer of Liver in 8 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes." | 5.36 | Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. ( Knupp, C; Quan, F; Quan, W; Walker, P, 2010) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 5.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes." | 5.32 | High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma. ( Jackson, S; Khan, N; Quan, W; Ramirez, M; Taylor, WC; Vinogradov, M, 2004) |
| "Although the beneficial effect of cimetidine on survival in cancer has been clinically demonstrated in colorectal cancer patients, the mode of action of cimetidine has not been elucidated." | 3.70 | Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. ( Kawabe, T; Kobayashi, K; Matsumoto, S; Morishima, T; Okamoto, T, 2000) |
| "Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes." | 1.36 | Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. ( Knupp, C; Quan, F; Quan, W; Walker, P, 2010) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 1.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes." | 1.32 | High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma. ( Jackson, S; Khan, N; Quan, W; Ramirez, M; Taylor, WC; Vinogradov, M, 2004) |
| "Unresectable hepatocellular carcinoma (HCC) has a poor prognosis and little sensitivity to anticancer agents." | 1.28 | [Intraarterial combination immunotherapy in hepatocellular carcinoma]. ( Hazama, S; Iizuka, N; Murakami, T; Oka, M; Shimizu, R; Suzuki, T; Yano, K; Yoshino, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quan, W | 3 |
| Knupp, C | 1 |
| Quan, F | 2 |
| Walker, P | 2 |
| Ramirez, M | 2 |
| Taylor, WC | 1 |
| Vinogradov, M | 2 |
| Khan, N | 1 |
| Jackson, S | 1 |
| Taylor, C | 1 |
| Quan, WD | 1 |
| Quan, FM | 1 |
| King, LA | 1 |
| Walker, PR | 1 |
| Kanakia, RR | 1 |
| Sawant, PD | 1 |
| Nanivadekar, SA | 1 |
| Vishwanath, N | 1 |
| Rajagopalan, K | 1 |
| Shroff, CP | 1 |
| Oka, M | 2 |
| Hazama, S | 2 |
| Yoshino, S | 2 |
| Shimoda, K | 1 |
| Suzuki, M | 1 |
| Shimizu, R | 2 |
| Yano, K | 2 |
| Nishida, M | 1 |
| Suzuki, T | 2 |
| Kobayashi, K | 1 |
| Matsumoto, S | 1 |
| Morishima, T | 1 |
| Kawabe, T | 1 |
| Okamoto, T | 1 |
| Iizuka, N | 1 |
| Murakami, T | 1 |
2 trials available for famotidine and Cancer of Liver
| Article | Year |
|---|---|
Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
Topics: Adenosine; Aged; Aged, 80 and over; Aging; Capillary Leak Syndrome; Famotidine; Hemodynamics; Humans | 2005 |
Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results.
Topics: Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Famotidin | 1994 |
6 other studies available for famotidine and Cancer of Liver
| Article | Year |
|---|---|
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cycl | 2010 |
High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Drug Therapy, Combination; Famotidine; Female; H | 2004 |
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cycloph | 2008 |
Primary gastrinoma of the liver.
Topics: Child; Famotidine; Gastrinoma; Humans; Jejunostomy; Liver Neoplasms; Male; Zollinger-Ellison Syndrom | 1994 |
Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression.
Topics: Animals; Cell Adhesion; Cell Nucleus; Cimetidine; Colorectal Neoplasms; Dose-Response Relationship, | 2000 |
[Intraarterial combination immunotherapy in hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Hepatocellular; Cycl | 1990 |